May 14, 2019
Solid Biosciences tumbles 38% to hit historic low
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its lead investigational drug, SGT-001, spurred serious adverse event in a patient.
The drug has been in development to treat a rare muscle disorder known as Duchenne. However, in its latest patient, the drug caused certain liver problems, besides…
View On WordPress